Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 121562
Published online Sep 15, 2026. doi: 10.4251/wjgo.121562
Published online Sep 15, 2026. doi: 10.4251/wjgo.121562
Clinicopathological features and prognosis of gastric adenocarcinoma with enteroblastic differentiation
Ze-Lin Wen, Hu Ren, Peng-Hui Niu, He Fei, Ze-Feng Li, Dong-Bing Zhao, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Co-first authors: Ze-Lin Wen and Hu Ren.
Author contributions: Wen ZL and Ren H contributed equally to this manuscript and are co-first authors. Wen ZL, Ren H, Niu PH, Fei H, Li ZF and Zhao DB designed the research study; Wen ZL, Ren H, Niu PH, and Fei H performed the research and collected the data; Wen ZL, Ren H, and Niu PH analyzed the data; Wen ZL drafted the manuscript; Li ZF and Zhao DB critically revised the manuscript for important intellectual content and supervised the study; and all authors have read and approved the final manuscript.
AI contribution statement: The design, writing, data analysis, result interpretation, and chart generation of this article did not use any AI tools.
Supported by Beijing Hope Run Special Fund of Cancer Foundation of China, No. LC2022 L03.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No. 23/122-3864).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at
Corresponding author: Dong-Bing Zhao, Chief Physician, Professor, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.
Received: March 27, 2026
Revised: April 17, 2026
Accepted: May 25, 2026
Published online: September 15, 2026
Processing time: 152 Days and 1.1 Hours
Revised: April 17, 2026
Accepted: May 25, 2026
Published online: September 15, 2026
Processing time: 152 Days and 1.1 Hours
Core Tip
Core Tip: Gastric adenocarcinoma with enteroblastic differentiation (GAED) is a rare subtype of gastric cancer with distinct clinicopathological characteristics. In this retrospective study, GAED was associated with unique pathological features, a higher risk of recurrence or metastasis, and significantly poorer survival than conventional gastric adenocarcinoma. Notably, its adverse prognosis persisted despite lower rates of some traditional invasive pathological features. These findings suggest that GAED may represent a biologically distinct and clinically aggressive entity that requires closer follow-up and more individualized treatment strategies.